These sEVs produced by modified HEK293T cells combined with interleukin-3 (IL3) fragments were able to target IL3 receptor-rich chronic myeloid leukemia mother cells and inhibit their growth (109). The gene discussed is IL3; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.